Nanobiotix: Sees Clinical Advance In Soft Tissue Sarcoma Pilot Trial With Lead Product, NBTXR3 Market Development Plan Outlined For Earlier Potential Launch In 2016
2/11/2014 9:32:13 AM
PARIS, Feb. 10, 2014 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its development plan for the CE marking of NBTXR3, the first product from the NanoXray pipeline.
Help employers find you! Check out all the jobs and post your resume.
comments powered by